Inactive Instrument

Orletto Capital Inc Stock Toronto S.E.

Equities

OLEp

CA6866681043

Pharmaceuticals

End-of-day quote Toronto S.E.
- - Intraday chart for Orletto Capital Inc
Sales 2022 2.31M 1.69M 0 Sales 2023 2.35M 1.72M 0 Capitalization 39.73M 29.05M 0
Net income 2022 -3M -2.19M - Net income 2023 -4M -2.92M - EV / Sales 2022 24.1 x
Net cash position 2022 3.53M 2.58M 0 Net cash position 2023 1.39M 1.02M 0 EV / Sales 2023 16.3 x
P/E ratio 2022
-15.5 x
P/E ratio 2023
-8.09 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 85.8%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 64 23-03-16
Founder - 15-03-26
Director of Finance/CFO - 15-12-27
Members of the board TitleAgeSince
Founder - 15-03-26
Chief Executive Officer 64 23-03-16
Director/Board Member 62 02-27
More insiders
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.
More about the company